MNKD

MANNKIND CORP

14 filings tracked

healthcarebiotechnologySMALL ($300M-2B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

bullishMay 28

FDA released company from a massive 8,000-10,000 patient postmarketing safety study.

regulatory action

90%

neutralMay 28

Expansion of INHALE-1st trial sites to accelerate pediatric data collection.

management change

20%

bullishMay 22

Full board re-election provides leadership continuity.

management change

60%

neutralMay 22

Routine ratification of independent auditors.

regulatory action

30%

bullishMay 22

Full board re-election provides leadership continuity.

management change

60%

neutralMay 22

Routine ratification of independent auditors.

regulatory action

30%

bullishMay 22

Full board re-election provides leadership continuity.

management change

60%

neutralMay 22

Routine ratification of independent auditors.

regulatory action

30%

bullishMay 22

Full board re-election provides leadership continuity.

management change

60%

neutralMay 22

Routine ratification of independent auditors.

regulatory action

30%

bullishMay 22

Full board re-election provides leadership continuity.

management change

60%

neutralMay 22

Routine ratification of independent auditors.

regulatory action

30%

bullishMay 22

Full board re-election provides leadership continuity.

management change

60%

neutralMay 22

Routine ratification of independent auditors.

regulatory action

30%

bearishMay 6

GAAP net loss of $16.6 million compared to a profit in the prior year period.

earnings miss

60%

bearishMay 6

Commercial product gross margin slipped from 80% to 78%.

margin compression

30%

neutralMay 6

Settled senior convertible notes and moved to a $325M Blackstone term loan.

debt restructure

70%

bullishMay 6

Integration of scPharma driving significant growth in commercial product sales.

acquisition

80%

bearishMay 6

GAAP net loss of $16.6 million compared to a profit in the prior year period.

earnings miss

60%

bearishMay 6

Commercial product gross margin slipped from 80% to 78%.

margin compression

30%

neutralMay 6

Settled senior convertible notes and moved to a $325M Blackstone term loan.

debt restructure

70%

bullishMay 6

Integration of scPharma driving significant growth in commercial product sales.

acquisition

80%

bearishMay 6

GAAP net loss of $16.6 million compared to a profit in the prior year period.

earnings miss

60%

bearishMay 6

Commercial product gross margin slipped from 80% to 78%.

margin compression

30%

neutralMay 6

Settled senior convertible notes and moved to a $325M Blackstone term loan.

debt restructure

70%

bullishMay 6

Integration of scPharma driving significant growth in commercial product sales.

acquisition

80%

bearishMay 6

GAAP net loss of $16.6 million compared to a profit in the prior year period.

earnings miss

60%

bearishMay 6

Commercial product gross margin slipped from 80% to 78%.

margin compression

30%

neutralMay 6

Settled senior convertible notes and moved to a $325M Blackstone term loan.

debt restructure

70%

bullishMay 6

Integration of scPharma driving significant growth in commercial product sales.

acquisition

80%

bearishMay 6

GAAP net loss of $16.6 million compared to a profit in the prior year period.

earnings miss

60%

bearishMay 6

Commercial product gross margin slipped from 80% to 78%.

margin compression

30%

neutralMay 6

Settled senior convertible notes and moved to a $325M Blackstone term loan.

debt restructure

70%

bullishMay 6

Integration of scPharma driving significant growth in commercial product sales.

acquisition

80%

bearishMay 6

GAAP net loss of $16.6 million compared to a profit in the prior year period.

earnings miss

60%

bearishMay 6

Commercial product gross margin slipped from 80% to 78%.

margin compression

30%

neutralMay 6

Settled senior convertible notes and moved to a $325M Blackstone term loan.

debt restructure

70%

bullishMay 6

Integration of scPharma driving significant growth in commercial product sales.

acquisition

80%

bearishMay 6

GAAP net loss of $16.6 million compared to a profit in the prior year period.

earnings miss

60%

bearishMay 6

Commercial product gross margin slipped from 80% to 78%.

margin compression

30%

neutralMay 6

Settled senior convertible notes and moved to a $325M Blackstone term loan.

debt restructure

70%

bullishMay 6

Integration of scPharma driving significant growth in commercial product sales.

acquisition

80%

Filing History

8-KMay 28, 2026

The recent 8-K filing marks a critical transition for MannKind as it shifts from defensive regulatory compliance to offensive market expansion. The removal of the 8,000-patient study requirement is a clear de-risking event, though the immediate focus now shifts to the May 29, 2026, PDUFA date for pediatric use. Investors are weighing the relief of the waived study against the binary risk of the upcoming pediatric approval and the long-term data readouts expected in 2027.

8-KMay 22, 2026

The 8-K filing regarding the 2026 Annual Meeting confirms that MannKind's leadership remains intact, but it exposes a divide between official approval and actual investor sentiment. While the board and auditors were ratified, the substantial volume of non-votes and the 10% dissent in compensation votes create a nuanced picture of stability tempered by lingering skepticism. Investors are now weighing whether this represents a clean slate for growth or a fragile consensus masking deeper governance and financial tensions.

10-QMay 6, 2026

The Q1 2026 filing reveals a company in the midst of a high-stakes transformation. MannKind has successfully proven that its Technosphere platform can scale beyond Afrezza, but this growth has come at the cost of significant financial leverage and operational spend. The shift from convertible notes to a massive Blackstone term loan indicates a move toward a more mature, though more expensive, capital structure designed to fund aggressive commercialization. Ultimately, the investment thesis now hinges on execution. If the upcoming regulatory approvals for pediatric Afrezza and ReadyFlow translate into immediate market share gains, the company can outrun its debt and high fixed costs. However, if these launches stall or if United Therapeutics reduces its emphasis on Tyvaso DPI, the company's thin margin for error could lead to a liquidity crisis. Investors are essentially betting on the commercial scalability of the scPharma acquisition to offset a fragile balance sheet.